Roche reports 7% growth in its top-line for both Q2 (to CHF14.5bn) and H1 18 (to CHF28.1bn). Both the pharma and diagnostics businesses grew at 7% during the quarter, both in CER as well as reported. The US and international markets have been in the driving seat while Europe was debilitated by the biosimilar impact. Reported-core EPS for H1 grew by 8% (+19% including the effect of the US tax reform). Guidance upgraded again.
30 Jul 2018
Lucky number seven leads to guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Lucky number seven leads to guidance upgrade
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
30 Jul 2018 -
Author:
Kamla Singh -
Pages:
3
Roche reports 7% growth in its top-line for both Q2 (to CHF14.5bn) and H1 18 (to CHF28.1bn). Both the pharma and diagnostics businesses grew at 7% during the quarter, both in CER as well as reported. The US and international markets have been in the driving seat while Europe was debilitated by the biosimilar impact. Reported-core EPS for H1 grew by 8% (+19% including the effect of the US tax reform). Guidance upgraded again.